Electronic consent or eConsent refers to the process of using electronic systems and processes to convey information related to the study and to obtain and document participant consent. While eConsent brings numerous benefits to the table, such as improved participant comprehension, streamlined workflows, and easier tracking and managing of consent versions, it is not universally accepted in Real-World Evidence (RWE) studies due to several reasons:
[1] Regulatory Variations: Regulatory guidelines and requirements vary across different jurisdictions and countries. Some regions may not yet have clear guidance or regulations that specifically endorse eConsent, causing uncertainty about its legal validity.
[2] Digital Divide: While digital technologies are pervasive (increasingly accepted), access to and familiarity with these technologies is not universal. Some potential study participants may lack the technology needed for eConsent or may not be comfortable using it, which could potentially exclude certain populations from participation (introducing bias).
[3] Data Security and Privacy Concerns: As with any digital system, there are concerns related to data security and privacy. Participants may worry about their personal information being mishandled or leaked, especially given the sensitivity of health data.
[4] Implementation Costs: Setting up a secure, user-friendly eConsent system that can also meet all regulatory requirements is a significant investment. Small research entities or those in low-resource settings might find it challenging to bear these costs.
[5] Technical Hurdles: eConsent systems require a level of technical infrastructure and support to function effectively. This can include the need for reliable internet connectivity, ongoing technical support, regular software updates, and more.
Despite these challenges, the adoption of eConsent is increasing due to the evolution of technology, better regulatory support, and the COVID-19 pandemic necessitating remote study processes. As these challenges are addressed over time, it’s expected that eConsent will become a more universally accepted practice in RWE studies.
Share this story...
Real World Evidence (RWE) 101 – Ethical Imperatives (CIOMS 2023)
RWE 101 - Ethical Imperatives (CIOMS 2023) Informed decision making with patients typically relies on evidence from clinical trials that describe the likely benefits and toxicities. However, patients treated [...]
Real World Evidence (RWE) 101 – Ethical Imperatives
RWE 101 - Ethical Imperatives Real-world evidence (RWE) refers to the clinical evidence regarding the usage and potential benefits or risks of a product derived from analysis of real-world [...]
Real World Evidence (RWE) 101 – The Importance of Intent
RWE 101 - The Importance of Intent Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a product derived from the analysis [...]
Real World Evidence (RWE) 101 – Inspections
RWE 101 - Inspections Real-World Evidence (RWE) can include data from sources such as electronic health records (EHRs), insurance claims and billing activities, patient registries, patient-generated data, and data [...]
Real World Evidence (RWE) 101 – Audits
RWE 101 - Audits A quality assurance auditor in the context of a real-world evidence (RWE) study has several responsibilities, key among them ensuring that all facets of the [...]
Real World Evidence (RWE) 101 – Compliance Maps
RWE 101 - Compliance Maps In the context of multi-country Real-World Evidence (RWE) studies, "Regulatory Compliance Maps" are essentially a detailed representation of the diverse regulatory requirements specific to [...]







